In this 4-part on-demand webinar, leading medical experts from the US and UK come together to discuss the current gastroesophageal cancer treatment landscape and near-future developments.

Watch the videos, download the slides and access the e-learning using the blue button below the videos.

  • The discussion opens with an overview of gastric and gastroesophageal cancer from Dr Yelena Janjigian
  • Dr Sam Klempner and Dr Lizzy Smyth present case studies outlining treatment, biomarker selection and adverse event management for localised and metastatic disease
  • Experts engage in an insightful panel discussion and answer pressing questions

Would you make the same clinical decisions as your peers?

Find out by watching the interactive case-based discussion and downloading the accompanying slides below, then take the e-learning to earn a CME credit.

Yelena Y. Janjigian MD, is Associate Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of oesophagus and stomach and lead several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for oesophagogastric cancer pathogenesis and secure federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date.

Dr Janjigian received her BS from the University of California, San Diego and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her haematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service.

Dr Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr Janjigian’s mission is to foster research and innovation that transform the future of GI oncology to help patients worldwide. 

Dr Yelena Janjigian has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Research Funding: Bayer, Bristol-Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred’s Team, Genentech/Roche, Merck, NCI, RGENIX

Advisory Boards/Consulting: Amerisource Bergen, Arcus Biosciences, AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Eli Lilly, Geneos Therapeutics, GlaxoSmithKline, Imedex, Imugene, Lynx Health, Merck, Merck Serono, Michael J. Hennessy Associates, Paradigm Medical Communications, PeerView Institute, Pfizer, Research to Practice, RGENIX, Seagen, Silverback Therapeutics, Zymeworks Inc.

Other: RGENIX (stock options)

 

Elizabeth (Lizzy) Smyth is a consultant in gastrointestinal oncology. Dr Smyth commenced her oncology training in Dublin, Ireland. In 2009 she was awarded a fellowship from the Irish Society of Medical Oncology to train at Memorial Sloan-Kettering Centre, New York. Following this, she worked at the Royal Marsden Hospital in London from 2011-2018. Her research focus is on clinical trials and translational research in gastroesophageal cancer, and she has worked on trial design and management of national and international trials. She is a member of the European Society for Medical Oncology GI Faculty and leads the EORTC GI Trials Group Gastric Cancer Taskforce. Dr Smyth is committed to furthering national and international collaboration in GI trials research.

Dr Elizabeth Smyth has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amal Therapeutics, Aptitude Health, Amgen, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Daiichi Sankyo, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Pfizer, Roche, Sai-Med, Servier, Viracta, Zymeworks

Dr. Klempner is an Associate Professor at Massachusetts General Hospital and Harvard Medical School and leads the gastric and oesophageal programme. His clinical and translational research is centred on cancer genomics, acquired resistance to targeted therapies and the intersection of genomics and immune mediated therapies to identify novel therapeutic approaches and biomarkers in gastroesophageal cancers. He serves on the NRG non-colorectal committee, co-chairs the NCI oesophagogastric task force, and is on the NCCN guideline committees for gastric and oesophageal cancers. His work is supported by Stand Up 2 Cancer, NCI/NIH, AACR, the Degregorio Foundation, and The Gastric Cancer Foundation and Gateway for Cancer Research. He is active in gastric and oesophageal cancer outreach and patient advocacy.

Assoc. Prof. Samuel J Klempner has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, AstraZeneca, BMS, Coherus, Daiichi-Sankyo, Eli Lilly, Merck, Novartis, Nuvalent Therapuetics and Sanofi.

Programme summary
  • clock Duration 19 MIN
  • clock Language(s) flag
Take the e-learning now
Other episodes in this series
Current and Future Gastroesophageal Cancer Treatments

Current and Future Gastroesophageal Cancer Treatments

Episode 1: Overview of Gastroesophageal Cancer

Current and Future Gastroesophageal Cancer Treatments

Current and Future Gastroesophageal Cancer Treatments

Episode 2: Non-metastatic Gastroesophageal Cancers

Current and Future Gastroesophageal Cancer Treatments

Current and Future Gastroesophageal Cancer Treatments

Episode 3: Metastatic Gastroesophageal Cancers

Current Episode
Current and Future Gastroesophageal Cancer Treatments

Current and Future Gastroesophageal Cancer Treatments

Episode 4: Panel Discussion and Summary

Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre.  

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
podcast Podcast

Episode

2

of 2

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Dr Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery Global Liver Institute
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
Testing to treatment of BRAF-mutant metastatic NSCLC

Medical experts share their insights on testing and treatment

Experts
Prof. David Planchard, Dr Federico Cappuzzo
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. This content is intended for HCPs outside the UK & ROI only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
HCC podcast series part 1: The use of IO in unresectable HCC

Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice

Experts
Dr Rachna Shroff, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.